The Scientist

» biotech

Most Recent

image: Incentivizing Breakthroughs

Incentivizing Breakthroughs

By | December 1, 2014

With scientific funding on shaky ground, big-dollar competitions offer a new way for life-science innovators to bring their ideas to fruition.

1 Comment

image: Roche Buys Biotech for $8.3B

Roche Buys Biotech for $8.3B

By | August 27, 2014

The pharma giant strikes a deal to acquire InterMune, a Brisbane, California-based biotech with only one product—a treatment for a fatal lung disease.

0 Comments

image: Biotech Terminates IPO

Biotech Terminates IPO

By | August 15, 2014

The Israeli firm Vascular Biogenics withdrew its initial public offering after six days of trading. 

0 Comments

image: Merck Snaps Up Biotech for $3.85B

Merck Snaps Up Biotech for $3.85B

By | June 10, 2014

The drug giant will acquire Cambridge, Massachusetts-based Idenix Pharmaceuticals, which is focused on developing treatments for hepatitis C.

0 Comments

image: The Promise of Nanomedicine

The Promise of Nanomedicine

By | April 8, 2014

At AACR, scientists discuss the growing interest in nanotechnology and how it can be used to study, diagnose, and treat cancer.

0 Comments

image: Incubator Boom

Incubator Boom

By | March 1, 2014

From San Francisco to St. Louis, biotech incubators are proliferating across North America. Can they deliver on their promise of fueling the economy?  

1 Comment

image: New Year’s Biotech IPO Boom?

New Year’s Biotech IPO Boom?

By | February 3, 2014

January was a profitable month for biotech companies going public, Burrill & Company says.

5 Comments

image: Penetrating the Brain

Penetrating the Brain

By | November 1, 2013

Researchers use molecular keys, chisels, and crowbars to open the last great biochemical barricade in the body—the blood-brain barrier.

1 Comment

image: Geron’s Stem Cell Program Sold

Geron’s Stem Cell Program Sold

By | October 2, 2013

The company, which launched the first ever clinical trial for a human embryonic stem cell therapy before shuttering its stem cell arm, has finally struck a deal with BioTime.

0 Comments

image: Remaking a Classic

Remaking a Classic

By | September 1, 2013

Companies are bursting at the seams with tools to engineer pharma’s next magic bullet: the new and improved antibody.

0 Comments

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Mettler Toledo
Mettler Toledo
Advertisement
PITTCON
PITTCON
Life Technologies